408 related articles for article (PubMed ID: 1778305)
1. Protective immunogenicity of synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
Dev Biol Stand; 1991; 73():111-20. PubMed ID: 1778305
[TBL] [Abstract][Full Text] [Related]
2. Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
Askelöf P; Rodmalm K; Wrangsell G; Larsson U; Svenson SB; Cowell JL; Undén A; Bartfai T
Proc Natl Acad Sci U S A; 1990 Feb; 87(4):1347-51. PubMed ID: 2304902
[TBL] [Abstract][Full Text] [Related]
3. Characterization of mutant strains producing pertussis toxin cross reacting materials.
Sato Y; Sato H; Chazono M; Ginnaga A; Tamura C
Dev Biol Stand; 1991; 73():93-107. PubMed ID: 1778339
[TBL] [Abstract][Full Text] [Related]
4. Relationship between structure and biological and protective activities of pertussis toxin.
Sato H; Sato Y
Dev Biol Stand; 1991; 73():121-32. PubMed ID: 1723387
[TBL] [Abstract][Full Text] [Related]
5. Multiple T and B cell epitopes in the S1 subunit ("A"-monomer) of the pertussis toxin molecule.
Oksenberg JR; Ko C; Judd AK; Lim M; Kent A; Schoolnik GK; Steinman L
J Immunol; 1989 Dec; 143(12):4227-31. PubMed ID: 2480389
[TBL] [Abstract][Full Text] [Related]
6. Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis.
Sato H; Sato Y
Dev Biol Stand; 1985; 61():461-7. PubMed ID: 2872127
[TBL] [Abstract][Full Text] [Related]
7. Elucidation of linear epitopes of pertussis toxin using overlapping synthetic decapeptides: identification of a human B-cell determinant in the S1 subunit indicative of acute infections.
Raupach B; Schmidt MA
Microb Pathog; 1994 Oct; 17(4):213-26. PubMed ID: 7536288
[TBL] [Abstract][Full Text] [Related]
8. Induction of CD4(+) and CD8(+) Bordetella pertussis toxin subunit S1 specific T cells by immunization with synthetic peptides.
Fagerberg J; Askelöf P; Wigzell H; Mellstedt H
Cell Immunol; 1999 Sep; 196(2):110-21. PubMed ID: 10527563
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies against the enzymatic subunit of both pertussis and cholera toxins.
Kenimer JG; Probst PG; Karpas AB; Burns DL; Kaslow HR
Dev Biol Stand; 1991; 73():133-41. PubMed ID: 1778307
[TBL] [Abstract][Full Text] [Related]
10. Development of safer pertussis DNA vaccine expressing non-toxic C180 polypeptide of pertussis toxin S1 subunit.
Kamachi K; Arakawa Y
Vaccine; 2007 Jan; 25(6):1000-6. PubMed ID: 17050047
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis.
Morokuma K; Ginnaga A; Nishihara T; Tsunoda S; Furukawa M; Aihara K; Sakoh M
Dev Biol Stand; 1991; 73():223-32. PubMed ID: 1685713
[TBL] [Abstract][Full Text] [Related]
12. Identification of T- and B-cell epitopes of the S2 and S3 subunits of pertussis toxin by use of synthetic peptides.
Chong P; Zobrist G; Sia C; Loosmore S; Klein M
Infect Immun; 1992 Nov; 60(11):4640-7. PubMed ID: 1383153
[TBL] [Abstract][Full Text] [Related]
13. Production and purification of Bordetella pertussis toxin.
Ju CL; Sheu GC; Cheng Y; Lu CH
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1997 May; 30(2):72-83. PubMed ID: 10592813
[TBL] [Abstract][Full Text] [Related]
14. A quantitative analysis for the ADP-ribosylation activity of pertussis toxin: an enzymatic-HPLC coupled assay applicable to formulated whole cell and acellular pertussis vaccine products.
Cyr T; Menzies AJ; Calver J; Whitehouse LW
Biologicals; 2001 Jun; 29(2):81-95. PubMed ID: 11580213
[TBL] [Abstract][Full Text] [Related]
15. DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice.
Kamachi K; Konda T; Arakawa Y
Vaccine; 2003 Nov; 21(31):4609-15. PubMed ID: 14575775
[TBL] [Abstract][Full Text] [Related]
16. Construction and characterization of genetically inactivated pertussis toxin.
Brown DR; Keith JM; Sato H; Sato Y
Dev Biol Stand; 1991; 73():63-73. PubMed ID: 1778335
[TBL] [Abstract][Full Text] [Related]
17. Antibody responses after vaccination and disease against leukocytosis promoting factor, filamentous hemagglutinin, lipopolysaccharide and a protein binding to complement-fixing antibodies induced during whooping cough.
Winsnes R; Lønnes T; Møgster B; Berdal BP
Dev Biol Stand; 1985; 61():353-65. PubMed ID: 2872124
[TBL] [Abstract][Full Text] [Related]
18. Engineering bacterial toxin for the development of new vaccine against pertussis.
Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of antibodies elicited by immunization with pertussis toxin.
Kaslow HR; Schlotterbeck JD; Gotto J
Dev Biol Stand; 1991; 73():143-50. PubMed ID: 1778308
[TBL] [Abstract][Full Text] [Related]
20. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
Gupta RK; Saxena SN; Sharma SB; Ahuja S
Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
